Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

Dumass Apr. 24 at 4:09 PM

$FBIOP If I didn't already have an overly full position, I would still add here. Someone needs to know this.

1 · Reply

TimmyH67 Apr. 24 at 1:01 PM

$FBIOP is anyone getting any response from investor relations? I’ve sent two emails asking what seems to be valid questions and haven’t even received an acknowledgement that they received them.

4 · Reply

thesaltier1 Apr. 23 at 5:59 PM

$FBIOP anyone watching what $ATXI is doing, small trades have sent it up 400% in the last few months,

1 · Reply

Hedgehog13 Apr. 22 at 1:31 AM

$FBIOP Looks like selling is less and less in the last few days, we're holding steady above $13. If the common stock stays week - good for FBIOP, if the common goes up - always good for the preffered stock. Only one direction from here!

0 · Reply

Chaka1647 Apr. 17 at 9:33 PM

As a $FBIOP shareholder, I am glad that $FBIO is so weak. Really making the point that you need to cure the cap stack / preferred before the commons work

2 · Reply

makrodimutross Apr. 17 at 5:03 PM

$FBIO $FBIOP looks like this snip caught traction on an X account. https://x.com/i/status/2044480595460231196 Excited for this year.

0 · Reply

makrodimutross Apr. 14 at 4:00 PM

$FBIO $FBIOP Here is the raw data from the 13F-HR/A filing from Opaleye. I am very impressed that these guys have returned, and I stand corrected that LR would be "unable to find institutional interest with the preferred shares suspended". For him to get Opaleye back on board is a major milestone for capital market trust. Congratulations to the management team for getting them back on board.

4 · Reply

makrodimutross Apr. 10 at 10:57 PM

$FBIOP this is like me, too. Because Lindsay Rosenwald is most definitely NOT retarded. And if LR isn't retarded, the market must be.

1 · Reply

makrodimutross Apr. 10 at 9:08 PM

$FBIOP The price of this is remains fundamentally retarded and detached from reality. Day 0+1m on the suspension, this was trading in the 6.60 dollar range. There was only 19 cents accrued to the arrears, so the spec value was 6.41. (August 2024) Now, there are 21 months of accrued dividends, totaling 4.10 per share, and a sold PRV for 100m in proceeds to $FBIO... and the spec value now is 9.58 ($13.68 less the $4.10 per share) If the market is valuing the arrears as good money, that means its valuing the share itself as only 38.3% its full value (9.58 out of 25 dollars). The only way this price remains fundamentally retarded and detached from reality, is if Lindsay Rosenwald is fundamentally retarded and detached from reality. Either the capital markets are retarded, or Lindsay Rosenwald is. Which is it?

3 · Reply

FinSUN Apr. 10 at 2:34 PM

$FBIOP

0 · Reply

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

DERM

Mar 31, 2026, 4:05 PM EDT - 24 days ago

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

FBIOP

Mar 30, 2026, 4:05 PM EDT - 25 days ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Mar 25, 2026, 4:01 PM EDT - 4 weeks ago

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

DERM

Mar 18, 2026, 8:30 AM EDT - 5 weeks ago

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

DERM

Feb 23, 2026, 9:24 AM EST - 2 months ago

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

Feb 23, 2026, 8:30 AM EST - 2 months ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

Feb 23, 2026, 8:00 AM EST - 2 months ago

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Jan 13, 2026, 7:45 AM EST - 3 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

FBIOP

Dec 15, 2025, 8:00 AM EST - 4 months ago

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Dec 10, 2025, 8:30 AM EST - 4 months ago

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

DERM

Nov 14, 2025, 8:30 AM EST - 5 months ago

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Nov 12, 2025, 4:30 PM EST - 5 months ago

Fortress Biotech Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:01 PM EST - 5 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Nov 6, 2025, 7:00 AM EST - 6 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

AXSM

Nov 5, 2025, 8:30 AM EST - 6 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

DERM

Oct 24, 2025, 8:30 AM EDT - 6 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

DERM

Oct 21, 2025, 8:30 AM EDT - 6 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

FBIOP

Oct 8, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

DERM

Oct 1, 2025, 3:45 PM EDT - 7 months ago

Fortress Biotech Investigated by the Portnoy Law Firm

Oct 1, 2025, 8:05 AM EDT - 7 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

FBIOP

Oct 1, 2025, 8:00 AM EDT - 7 months ago

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

FBIOP

Sep 3, 2025, 8:30 AM EDT - 8 months ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

DERM

Sep 2, 2025, 8:30 AM EDT - 8 months ago

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FBIOP

Aug 18, 2025, 8:30 AM EDT - 8 months ago

Journey Medical Corporation to Present at the Emerging Growth Conference

DERM

Aug 14, 2025, 4:05 PM EDT - 9 months ago

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Aug 7, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

DERM

Aug 5, 2025, 4:01 PM EDT - 9 months ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

DERM

Jul 14, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

DERM

Jun 24, 2025, 8:30 AM EDT - 10 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

DERM

Jun 20, 2025, 8:30 AM EDT - 11 months ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

DERM

Jun 17, 2025, 10:00 AM EDT - 11 months ago

Fortress Biotech Transcript: AGM 2025

Jun 9, 2025, 8:30 AM EDT - 11 months ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

DERM

May 30, 2025, 10:47 AM EDT - 11 months ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIOP

May 15, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

May 14, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

May 13, 2025, 4:15 PM EDT - 1 year ago

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

CKPT

May 7, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

DERM

May 7, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIOP

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

DERM

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

CKPT

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Fortress Biotech Earnings Call Transcript: Q4 2024

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

DERM

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

DERM

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

DERM

Mar 17, 2025, 8:55 AM EDT - 1 year ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FBIOP

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

DERM

Mar 9, 2025, 10:06 PM EDT - 1 year ago

Sun Pharma to Acquire Checkpoint Therapeutics

CKPT

May 23, 2024, 10:00 AM EDT - 2 years ago

Fortress Biotech Transcript: AGM 2024

Dumass Apr. 24 at 4:09 PM

$FBIOP If I didn't already have an overly full position, I would still add here. Someone needs to know this.

1 · Reply

TimmyH67 Apr. 24 at 1:01 PM

$FBIOP is anyone getting any response from investor relations? I’ve sent two emails asking what seems to be valid questions and haven’t even received an acknowledgement that they received them.

4 · Reply

thesaltier1 Apr. 23 at 5:59 PM

$FBIOP anyone watching what $ATXI is doing, small trades have sent it up 400% in the last few months,

1 · Reply

Hedgehog13 Apr. 22 at 1:31 AM

0 · Reply

Chaka1647 Apr. 17 at 9:33 PM

As a $FBIOP shareholder, I am glad that $FBIO is so weak. Really making the point that you need to cure the cap stack / preferred before the commons work

2 · Reply

makrodimutross Apr. 17 at 5:03 PM

$FBIO $FBIOP looks like this snip caught traction on an X account. https://x.com/i/status/2044480595460231196 Excited for this year.

0 · Reply

makrodimutross Apr. 14 at 4:00 PM

4 · Reply

makrodimutross Apr. 10 at 10:57 PM

$FBIOP this is like me, too. Because Lindsay Rosenwald is most definitely NOT retarded. And if LR isn't retarded, the market must be.

1 · Reply

makrodimutross Apr. 10 at 9:08 PM

3 · Reply

FinSUN Apr. 10 at 2:34 PM

$FBIOP

0 · Reply

makrodimutross Apr. 9 at 9:06 PM

under 3000 shares of $FBIOP traded today. Sellers and Holders are saying to themselves: "This is essentially clear cash in 12 months, how could this possibly be a sell?" Buyers are saying to themselves: "Shit, if 100m in cash to $FBIO isn't enough to restart the dividends, what WOULD be enough?"

0 · Reply

Sawnchey Apr. 7 at 3:21 PM

$FBIO $FBIOP 3. As of Dec 2025 Fortress (the parent company and non-public subsidiaries only) had roughly ~70m of Assets of and ~45m of debt and unpaid dividends. Since then Fortress has recieved over 100m in PRV proceeds and used some to pay down the notes. So net-of-obligation you have a company with about 125m in assets which burns 3m per quarter as of Q4. They are under no financial pressure at this time, even if they restored the dividend they could go another 2 years easily before needing to tap the markets for more cash. 4. As of today the combined market cap of FBIO and FBIOP is about 115m. This isn't the company in distress or failing, the market has just got it wrong. On days like this I just buy and wait.

1 · Reply

Sawnchey Apr. 7 at 2:56 PM

$FBIO $FBIOP Rumours of the company's demise are much exaggerated. A few points: 1. The company is in a far stronger position than it was 1 year ago. They have significantly more assets, less debt and from this quarter onwards the income from Unloxcyt and Zycubo royalties will begin trickling in. 2. I put a 0% chance on the preferred stock being converted into commons as a PiK redemption. I have said previously that trying to redeem the shares (via cash) would be completely foolish, as you are effectively paying 10x the annual dividend upfront (12x at present with the accumulated dividend). The only real benefits in removing the preferred class is A. To remove a ~7.5m annual obligation and B. Bump the Common stock price, and C. Regain access to dilutive financing. So the juice is clearly not worth the squeeze (especially when committing capital suicide via PiK conversion) because you eliminate benefits B and C. The management is silent and the vaccuum is being filled by panic

0 · Reply

FinSUN Apr. 7 at 2:17 PM

$FBIO $FBIOP Where is the great expert makrobiotich? 🤣 I have been the only one being right long last year and short now... where is he hiding ?

1 · Reply

Dumass Apr. 7 at 12:22 PM

$FBIOP Patience is all you need. If this $MINDP or $WHLRD instead of $CCLDO the returns are still great long term

0 · Reply

makrodimutross Apr. 6 at 3:25 PM

$FBIO The capital markets back then thought "Surely, this will now be the time to submit a plan to make good to holders of $FBIOP and clear the arrears". I think even the capital markets are shocked at LR's unwillingness to read the room. Does he honestly think he's going to get to a 1b+ market cap with SUSPENDED DIVIDENDS TO PREFERRED STOCKHOLDERS? It is an absolute joke, and very difficult to believe from someone with such a maverick biotech history.

3 · Reply

makrodimutross Apr. 2 at 7:42 PM

$FBIO $FBIOP Order of Events Required: 1.) Company receives its special dividend from Cyprium (100m+ according to management). 2.) Company pays down Oaktree to 15m balance. 3.) Company makes good on arrears outstanding to the preferred stockholders 14.3m. 4.) Company presents positive P2 Triplex data 1H2026. This will most likely get you what you're looking for. Not financial advice.

1 · Reply

MomFundsTheTrip Apr. 2 at 4:38 PM

$FBIO, $FBIOP exactly!!

0 · Reply

justbaseball25 Apr. 2 at 3:04 PM

Added 25 more $PFFA 5 $ULTY 0 $FBIO because I don't like that they could change the prospectus to make the common holders pay for $FBIOP

1 · Reply

Alex1m2 Apr. 2 at 1:22 PM

$FBIOP This is free money right now. Just buy all you can and sit tight until the inevitable good news arrive.

1 · Reply

hhkjljgog Apr. 2 at 11:48 AM

$FBIO, $FBIOP quick clarification on FBIOP dividends since there’s a lot of confusion: The Series A Preferred is cumulative, so unpaid dividends accrue over time and must eventually be paid. Importantly, there is no indication in the prospectus that dividends can be paid in stock (no PIK language). The terms consistently refer to “accrued and unpaid dividends” and redemption is defined as $25 + accrued dividends in cash. That strongly implies: Dividends are intended to be paid in cash, not shares There is no automatic mechanism of payment in FBIO stock that means no expected dillution.

3 · Reply

FinSUN Apr. 1 at 7:24 PM

$FBIOP

0 · Reply

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A